1	Subject has been maintained on a stable dose of levetiracetam LEV and a sodium channel blocking antiepileptic drug SCB-AED for at least 4 weeks prior to the Screening Visit Visit 1 and during the 4-week Prospective Seizure Baseline with or without additional concurrent stable vagal nerve stimulation|LEV[62,65]|||||||||C3220305|1166072|5032|guaifenesin
1	Subject has been maintained on a stable dose of levetiracetam LEV and a sodium channel blocking antiepileptic drug SCB-AED for at least 4 weeks prior to the Screening Visit Visit 1 and during the 4-week Prospective Seizure Baseline with or without additional concurrent stable vagal nerve stimulation|levetiracetam[48,61]|||||||||C0377265|114477|114477|levetiracetam
1	Subject has been maintained on a stable dose of levetiracetam LEV and a sodium channel blocking antiepileptic drug SCB-AED for at least 4 weeks prior to the Screening Visit Visit 1 and during the 4-week Prospective Seizure Baseline with or without additional concurrent stable vagal nerve stimulation|antiepileptic[96,109]|||||||4 weeks[136,143]||C0003299|932|932|antiepileptic
1	Subject has been maintained on a stable dose of levetiracetam LEV and a sodium channel blocking antiepileptic drug SCB-AED for at least 4 weeks prior to the Screening Visit Visit 1 and during the 4-week Prospective Seizure Baseline with or without additional concurrent stable vagal nerve stimulation|sodium[72,78]|||||||||C0037473|9853|9853|sodium
